NCT02412631View on ClinicalTrials.gov

Addressing Post Cessation Weight Gain

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

April 17, 2020

Study Completion Date

April 17, 2020

Conditions
ObesitySmoking Cessation
Interventions
DRUG

lorcaserin

lorcaserin is an FDA-approved weight loss medication for overweight and obese patients

DRUG

Varenicline

Chantix is an FDA approved medication for smoking cessation

DRUG

Placebo

Placebo for lorcaserin

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Mayo Clinic

OTHER